Construction of PANoptosis signature: Novel target discovery for prostate cancer immunotherapy

作者：Xianyanling Yi, Jin Li, Xiaonan Zheng, Hang Xu, Dazhou Liao, Tianyi Zhang, Qiang Wei, Hong Li, Jiajie Peng, Jianzhong Ai · 发表于：Molecular Therapy — Nucleic Acids · 年份：2023 · DOI：10.1016/j.omtn.2023.07.010 · 被引用次数：66 · 研究领域：Inflammasome and immune disorders、Ferroptosis and cancer prognosis、Circular RNAs in diseases

PANoptosis pathway gene sets encompassing pyroptosis, apoptosis, and necroptosis were identified from the MSigDB database. We analyzed the perturbations and crosstalk in the PANoptosis pathway in prostate adenocarcinoma (PRAD), including gene mutation, transcription, methylation, and clinical features. By constructing a PANoptosis signature, we accurately predicted the prognosis and immunotherapeutic response of PRAD patients. We further explored the molecular features and immunological roles of the signature, dividing patients into high- and low-score groups. Notably, the high-score group correlated with better survival outcomes and immunotherapeutic responses, as well as a higher mutation frequency and enrichment score in the PANoptosis and HALLMARK pathways. The PANoptosis signature also enhanced overall antitumor immunity, promoted immune cell infiltration, upregulated immune checkpoint regulators, and revealed the cold tumor characteristics of PRAD. We also identified potential drug targets based on the PANoptosis signature. These findings lead the way in identifying novel prognostic markers and therapeutic targets for patients with PRAD.